Comparison of deep vein thrombosis risks in acute respiratory distress syndrome caused by COVID-19 and bacterial pneumonia: a retrospective cohort study

被引:6
作者
Cui, Na [1 ,2 ]
Jiang, Chunguo [1 ,2 ]
Yang, Chenlu [3 ]
Zhang, Liming [1 ,2 ]
Feng, Xiaokai [1 ,2 ,4 ]
机构
[1] Capital Med Univ, Dept Resp & Crit Care Med, Beijing Inst Resp Med, 8 Gongren Tiyuchang Nanlua, Beijing 100020, Peoples R China
[2] Capital Med Univ, Beijing Chao Yang Hosp, 8 Gongren Tiyuchang Nanlua, Beijing 100020, Peoples R China
[3] Chinese Acad Med Sci, Sch Basic Med, Peking Union Med Coll, Inst Basic Med Sci,Dept Epidemiol & Biostat, Beijing, Peoples R China
[4] Qinghai Univ, Qinghai Prov Peoples Hosp, Dept Resp & Critical Care Med, 2 Gonghe Rd, Xining 810000, Qinghai, Peoples R China
关键词
Acute respiratory distress syndrome; Pneumonia; bacterial; COVID-19; Deep vein thrombosis; VENOUS THROMBOEMBOLISM; PREVALENCE; DALTEPARIN; DISEASE; INJURY;
D O I
10.1186/s12959-022-00386-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background High incidence of deep vein thrombosis (DVT) has been observed in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 and those by bacterial pneumonia. However, the differences of incidence and risk factors of DVT in these two groups of ARDS had not been reported before. Study design and methods We performed a retrospective cohort study to investigate the difference of DVT in incidence and risk factors between the two independent cohorts of ARDS and eventually enrolled 240 patients, 105 of whom with ARDS caused by COVID-19 and 135 caused by bacterial pneumonia. Lower extremity venous compression ultrasound scanning was performed whenever possible regardless of clinical symptoms in the lower limbs. Clinical characteristics, including demographic information, clinical history, vital signs, laboratory findings, treatments, complications, and outcomes, were analyzed for patients with and without DVT in these two cohorts. Results The 28-days incidence of DVT was higher in patients with COVID-19 than in those with bacterial pneumonia (57.1% vs 41.5%, P = 0.016). Taking death as a competitive risk, the Fine-Gray test showed no significant difference in the 28-day cumulative incidence of DVT between these two groups (P = 0.220). Fine-Gray competing risk analysis also showed an association between increased CK (creatine kinase isoenzyme)-MB levels (P = 0.003), decreased PaO2 (partial pressure of arterial oxygen)/FiO(2) (fraction of inspired oxygen) ratios (P = 0.081), increased D-dimer levels (P = 0.064) and increased incidence of DVT in COVID-19 cohort, and an association between invasive mechanical ventilation (IMV; P = 0.001) and higher incidence of DVT and an association between VTE prophylaxis (P = 0.007) and lower incidence of DVT in bacterial pneumonia cohort. The sensitivity and specificity of the corresponding receiver operating characteristic curve originating from the combination of CK-MB levels, PaO2/FiO(2) ratios, and D-dimer levels >= 0.5 mu g/mL were higher than that of the DVT Wells score (P = 0.020) and were not inferior to that of the Padua prediction score (P = 0.363) for assessing the risk of DVT in COVID-19 cohort. Conclusions The incidence of DVT in patients with ARDS caused by COVID-19 is higher than those caused by bacterial pneumonia. Furthermore, the risk factors for DVT are completely different between these two ARDS cohorts. It is suggested that COVID-19 is probably an additional risk factor for DVT in ARDS patients.
引用
收藏
页数:14
相关论文
共 47 条
[1]   COVID-19 and the Heart [J].
Akhmerov, Akbarshakh ;
Marban, Eduardo .
CIRCULATION RESEARCH, 2020, 126 (10) :1443-1455
[2]  
Aljuhani O, 2022, SAUDI PHARM J
[3]   SARS-CoV-2 inflames the heart. The importance of awareness of myocardial injury in COVID-19 patients [J].
Ammirati, Enrico ;
Wang, Dao Wen .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 311 :122-123
[4]   COVID-19 for the Cardiologist Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies [J].
Atri, Deepak ;
Siddiqi, Hasan K. ;
Lang, Joshua P. ;
Nauffal, Victor ;
Morrow, David A. ;
Bohula, Erin A. .
JACC-BASIC TO TRANSLATIONAL SCIENCE, 2020, 5 (05) :518-536
[5]   A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score [J].
Barbar, S. ;
Noventa, F. ;
Rossetto, V. ;
Ferrari, A. ;
Brandolin, B. ;
Perlati, M. ;
De Bon, E. ;
Tormene, D. ;
Pagnan, A. ;
Prandoni, P. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (11) :2450-2457
[6]   Understanding Infection-Induced Thrombosis: Lessons Learned From Animal Models [J].
Beristain-Covarrubias, Nonantzin ;
Perez-Toledo, Marisol ;
Thomas, Mark R. ;
Henderson, Ian R. ;
Watson, Steve P. ;
Cunningham, Adam F. .
FRONTIERS IN IMMUNOLOGY, 2019, 10
[7]   The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2 [J].
Chen, Liang ;
Li, Xiangjie ;
Chen, Mingquan ;
Feng, Yi ;
Xiong, Chenglong .
CARDIOVASCULAR RESEARCH, 2020, 116 (06) :1097-1100
[8]   Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J].
Chen, Nanshan ;
Zhou, Min ;
Dong, Xuan ;
Qu, Jieming ;
Gong, Fengyun ;
Han, Yang ;
Qiu, Yang ;
Wang, Jingli ;
Liu, Ying ;
Wei, Yuan ;
Xia, Jia'an ;
Yu, Ting ;
Zhang, Xinxin ;
Zhang, Li .
LANCET, 2020, 395 (10223) :507-513
[9]   Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study [J].
Christiansen, C. F. ;
Schmidt, M. ;
Lamberg, A. L. ;
Horvath-Puho, E. ;
Baron, J. A. ;
Jespersen, B. ;
Sorensen, H. T. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (09) :1449-1454
[10]   COVID-19 and its implications for thrombosis and anticoagulation [J].
Connors, Jean M. ;
Levy, Jerrold H. .
BLOOD, 2020, 135 (23) :2033-2040